Amneal Pharmaceuticals, Inc. AMRX
We take great care to ensure that the data presented and summarized in this overview for Amneal Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMRX
View all-
Ubs Group Ag21.8MShares$170 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.6MShares$114 Million0.0% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX12.3MShares$96 Million2.45% of portfolio
-
Black Rock Inc. New York, NY11.3MShares$87.9 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$83.5 Million2.48% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il8.89MShares$69.3 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.71MShares$36.7 Million0.01% of portfolio
-
Neuberger Berman Group LLC New York, NY3.79MShares$29.5 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.79MShares$29.5 Million0.0% of portfolio
-
State Street Corp Boston, MA3.51MShares$27.4 Million0.0% of portfolio
Latest Institutional Activity in AMRX
Top Purchases
Top Sells
About AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at AMRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 22
2024
|
John Kiely Director |
SELL
Open market or private sale
|
Direct |
17,058
-6.0%
|
$136,464
$8.38 P/Share
|
Nov 22
2024
|
John Kiely Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,506
+9.11%
|
$114,024
$4.76 P/Share
|
Nov 22
2024
|
Deborah M. Autor Director |
SELL
Open market or private sale
|
Direct |
33,229
-38.36%
|
$265,832
$8.34 P/Share
|
Nov 21
2024
|
Deborah M. Autor Director |
SELL
Open market or private sale
|
Direct |
6,771
-7.25%
|
$54,168
$8.41 P/Share
|
Nov 21
2024
|
Jason B. Daly SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,665
-100.0%
|
$109,320
$8.4 P/Share
|
Nov 15
2024
|
Jason B. Daly SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
43,657
-76.16%
|
$349,256
$8.61 P/Share
|
Aug 15
2024
|
Andrew S Boyer Executive Vice President |
SELL
Open market or private sale
|
Direct |
40,225
-13.55%
|
$281,575
$7.85 P/Share
|
Aug 14
2024
|
Nikita Shah Executive Vice President |
SELL
Open market or private sale
|
Direct |
100,000
-25.53%
|
$700,000
$7.75 P/Share
|
Aug 14
2024
|
Andrew S Boyer Executive Vice President |
SELL
Open market or private sale
|
Direct |
22,486
-7.04%
|
$157,402
$7.81 P/Share
|
May 17
2024
|
Deborah M. Autor Director |
SELL
Open market or private sale
|
Direct |
23,447
-20.07%
|
$140,682
$6.73 P/Share
|
May 16
2024
|
Deborah M. Autor Director |
SELL
Open market or private sale
|
Direct |
14,553
-11.08%
|
$87,318
$6.76 P/Share
|
May 10
2024
|
Deborah M. Autor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+36.78%
|
-
|
May 10
2024
|
Emily Peterson Alva Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+23.36%
|
-
|
May 10
2024
|
Shlomo Yanai Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+23.73%
|
-
|
May 10
2024
|
Ted C Nark Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+20.27%
|
-
|
May 10
2024
|
J Kevin Buchi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+22.58%
|
-
|
May 10
2024
|
Jeffrey P. George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+22.1%
|
-
|
May 10
2024
|
John Kiely Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+23.02%
|
-
|
May 10
2024
|
Paul M Meister Director |
BUY
Exercise of conversion of derivative security
|
Direct |
107,034
+12.82%
|
-
|
May 10
2024
|
Gautam Patel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,453
+3.6%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 1.33M shares |
---|---|
Bona fide gift | 1.6M shares |
Payment of exercise price or tax liability | 250K shares |
---|---|
Open market or private sale | 315K shares |
Other acquisition or disposition | 33.5M shares |